2,2-Di-tert-butyl-pyrrolidine | 92144-57-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2,2-Di-tert-butyl-pyrrolidine
• 英文别名: 2,2-Ditert-butylpyrrolidine
• CAS: 92144-57-5
• 化学式: C₁₂H₂₅N
• 分子量: 183.337
• InChiKey: YEEJKSUOGNIKIS-UHFFFAOYSA-N

物化性质

• 沸点：
  206.1±8.0 °C(Predicted)
• 密度：
  0.850±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-甲氧基-1-吡咯烷 、 叔丁基锂 以49%的产率得到
  参考文献：
  名称：

  ZEZZA, CH. A.;SMITH, M. B.;ROSS, B. A.;ARHIN, AKWASI;CRONIN, P. L. E., J. ORG. CHEM., 1984, 49, N 23, 4397-4399

  摘要：

  DOI：

文献信息

• PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：SHANGHAI BLUERAY BIOPHARMA CO., LTD.

  公开号：US20210053989A1

  公开（公告）日：2021-02-25

  Disclosed in the present disclosure are a pyrimidine-fused cyclic compound or a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer, solvate or isotope labeled compound thereof. Also provided in the present disclosure are a preparation method for the compound, a composition comprising the compound and a use of the compound for the preparation of a medicament for the prevention and/or treatment of a disease or condition associated with abnormal SHP2 activity.

  本公开涉及一种嘧啶融合的环状化合物或其药用可接受的盐、水合物、前药、立体异构体、溶剂合物或同位素标记化合物。本公开还提供了该化合物的制备方法、包含该化合物的组合物以及该化合物用于制备与异常SHP2活性相关的疾病或病况的药物的用途。
• HEPATITIS B ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20200377519A1

  公开（公告）日：2020-12-03

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了化合物的结构式（I），或其药学上可接受的盐，它们抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰HBV生命周期的功能，同时也可用作抗病毒剂。本发明还涉及含有上述化合物的药物组合物，用于给患有HBV感染的受试者使用。本发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• Compounds useful for treating neurodegenerative disorders
  申请人：Bronk Brian Scott

  公开号：US20130060020A1

  公开（公告）日：2013-03-07

  The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein R x is as defined and described herein, compositions thereof, and methods of using the same.

  本发明提供了公式I的化合物：或其药学上可接受的盐，其中Rxis的定义和描述如本文所述，以及其组合物和使用方法。
• MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20160271105A1

  公开（公告）日：2016-09-22

  Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组合物，可用作ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节因子（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。
• HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20160009744A1

  公开（公告）日：2016-01-14

  Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, R a , R a′ , R b , R c , X 1 , X 2 , X 3 , R d , Z 1 , and Z 2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

  本发明涉及化学实体，其为以下式（I）的化合物或其药学上可接受的盐；其中，Y、Ra、Ra′、Rb、Rc、X1、X2、X3、Rd、Z1和Z2具有本文所述的值，并在星号位置描绘的立体化学构型表示绝对立体化学。根据本发明的化学实体可用作Sumo激活酶（SAE）的抑制剂。进一步提供了包括本发明化合物的制药组合物以及使用这些组合物治疗增生性、炎症性、心血管和神经退行性疾病或疾患的方法。